HLA-C and neoplasm: Unfortunately, the use of these innovative cell therapies has also encountered several limitations: expensive, time‐consuming process of engineering and expanding T cells, as well as efficacy limitations arising from low major histocompatibility complex (MHC) expression on tumor cells, loss of target antigens, tumor heterogeneity, and immunosuppressive TME (50, 51).